NICHD Neonatal Research Network
63
4
7
45
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
15.9%
10 terminated/withdrawn out of 63 trials
81.8%
-4.7% vs industry average
33%
21 trials in Phase 3/4
38%
17 of 45 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (63)
The Budesonide in Babies (BiB) Trial
Role: lead
Neonatal Platelet Transfusion Threshold Trial
Role: lead
Generic Database of Very Low Birth Weight Infants
Role: lead
Continued Pressure for Alveolar Protection (CPAP Trial)
Role: lead
Cycled Phototherapy
Role: lead
Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)
Role: lead
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Role: lead
Transfusion of Prematures Trial
Role: lead
Milrinone in Congenital Diaphragmatic Hernia
Role: lead
Management of the PDA Trial
Role: lead
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
Role: lead
Hydrocortisone for BPD
Role: lead
Follow-up Visit of High Risk Infants
Role: lead
Preemie Hypothermia for Neonatal Encephalopathy
Role: lead
Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial
Role: lead
Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis
Role: lead
Donor Milk vs. Formula in Extremely Low Birth Weight (ELBW) Infants
Role: lead
Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)
Role: lead
Hydrocortisone for Term Hypotension
Role: lead
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Role: lead